The oncogenic activation of HER2 can be caused by HER2 protein over-expression, gene amplification, or gene mutation and occur in various malignant tumors, including breast (3, 4), gastric (5), non-small cell lung (6), bladder (7), ovarian (8), and pancreatic cancers (9). This evidence concerns the gene ERBB2 and cancer.